As of today, what is the value and feasibility of implementing each DCT solution?

- Tele-visits: 22
- Direct-to-participant shipping: 3
- Home health visits: 2
- Use of local labs and imaging centers: 1
Should decentralized elements be mandatory in all trials?

Yes: 8
No: 25
Closing poll: Reflecting on these challenges, what solutions or next steps are most important to consider?

- **EDUCATION, EDUCATION, EDUCATION on DCTs.**
  - Education for sites & patients. We need to support their understanding of what DCTs means for them, wants in for them.
  - Further collaboration across interest groups whether it be through forums like this, roundtable discussions, etc.

- **continue knowledge sharing and education on topics related to decentralized clinical trial solutions**
  - continue to work cross collaboratively to work through the challenges
  - Alignment on regulations and stakeholder education and training

- **Rebuilding trust by patients and their carers, families in research community, industry, and the healthcare system.**
  - Share what was learned/identified in this conference with broader audience. Keep dialog open.
  - shape regulatory landscape to enable DCTs more broadly
Closing poll: Reflecting on these challenges, what solutions or next steps are most important to consider?

- CTTI can work to make the regulatory environment more uniform across jurisdictions.
- Harmonization of regulation guidance
- Promoting more collaboration with all stakeholders (regulatory agencies, industry, clinics & trial participants)
- Coming up with a consolidated approach to address these challenges similar to Transcelerate - i.e. single protocol designs they have done. In using a similar approach with DCT, I think the challenges will be easier to address.
- Recasting DCT as evolving as opposed to novel - this will promote greater acceptance
- More standardization, how to start implementing.
- 1) Harmonization of regulations globally, 2) Terminology unification with training and education, 3) Operationalizing DCT, 4) Technology adoption, access, integration, usability.
- would be valuable to have Sponsors, CROs, Vendors break out separately (i.e. all sponsors together, CROs together, etc.) and see what the various challenges and things working... then synthesize...
- Further collaboration with various stakeholders to address everyone's perspective.
**Closing poll: Reflecting on these challenges, what solutions or next steps are most important to consider?**

<table>
<thead>
<tr>
<th>Category</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Educational, regulatory, and financial support</td>
<td>Provide support for the early adopters - educational, regulatory, and even financial, where possible.</td>
</tr>
<tr>
<td>Building education pieces</td>
<td>Building education pieces across the stakeholders</td>
</tr>
<tr>
<td>Harmonized guidance/approach</td>
<td>Harmonized guidance/approach from health authorities</td>
</tr>
<tr>
<td>Early involvement</td>
<td>Early involvement from all stakeholder groups</td>
</tr>
<tr>
<td>Developing educational materials</td>
<td>Developing educational materials about DCT that is targeted to different stakeholders.</td>
</tr>
<tr>
<td>Work with regulatory agencies</td>
<td>Work with regulatory agencies to help sponsors feel more comfortable that DCT solutions should be considered/incorporated into trials.</td>
</tr>
<tr>
<td>Education</td>
<td>Education - educating sites, patients - all stakeholders on what DCT means. That it is not all or nothing - meaning there is a hybrid component, outlining what the potential value is for the different stakeholders.</td>
</tr>
</tbody>
</table>

Develop a glossary/definitions (if it has not already been done by CTTI or others) so everyone is speaking the same language.